newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

  • Cogent Biosciences priced an underwritten public offering of 9,677,420 common stock shares at $31.00 per share & a $200.0 million convertible notes offering.
  • The equity offering was upsized from a previous $200.0 million share value target to the current size.
  • Net proceeds are estimated at approximately $475.3 million after deducting underwriting discounts, commissions, & offering expenses.
  • Underwriters received a 30-day option to purchase up to 1,451,613 additional equity shares or $30.0 million in additional convertible notes to cover over-allotments.
  • The equity offering is expected to close on November 13, 2025, while the convertible notes offering is expected to close on November 18, 2025.
  • The convertible notes carry a 1.625% annual interest rate, mature on November 15, 2031, & accrue interest payable semi-annually in arrears.
  • Initial conversion rate is 22.2469 shares per $1,000 principal amount, equivalent to a conversion price of approximately $44.95 per share.
  • Convertible notes may be redeemed by Cogent at any time on or after November 20, 2029, if specific stock price conditions are met.
  • Noteholders may require repurchase upon a "fundamental change" or convert notes at their option starting August 15, 2031.
  • Net proceeds will be used to repay $50 million of existing term loans, fund development & regulatory activities for bezuclastinib, support commercial launch efforts, & cover working capital.
  • J.P. Morgan, Jefferies, Leerink Partners, & Guggenheim Securities are joint book-running managers for the equity offering; LifeSci Capital & Raymond James also participated.
  • Jefferies & J.P. Morgan are joint book-running managers for the convertible notes offering.